Lisa Rydén

Completion axillary lymph node dissection for the identification of pN2–3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial

Quality assessment of radiotherapy in the prospective randomized SENOMAC trial

Serum copper, zinc and copper/zinc ratio in relation to survival after breast cancer diagnosis: A prospective multicenter cohort study

Matched analysis of circulating selenium with the breast cancer selenotranscriptome: a multicentre prospective study

Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trial

Autoimmunity to selenoprotein P predicts breast cancer recurrence

Serum selenium, selenoprotein P and glutathione peroxidase 3 as predictors of mortality and recurrence following breast cancer diagnosis: A multicentre cohort study

Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis

Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers

Refinement of breast cancer molecular classification by miRNA expression profiles

Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling

Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial

Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo – Meta-analyses on efficacy and adverse events based on randomized clinical trials

A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in gram-positive cases

Med1 plays a critical role in the development of tamoxifen resistance